Best speak to the company yourself regarding the dogs, but my guess is that they are focusing more on humans now that they have 3 phase II studies lined up.
The dogs was always a good 'speed to market' strategy given the preexisting safety profile in sheep (ie. it didn't harm the sheep or the dogs, so it probably won't harm humans) but that bonus has now been taken advantage of and now that PAA has enough evidence regarding humans alone to entice volunteers for the phase II trials, the smaller market of dogs has now taken back seat IMO..
I too would still like more info regarding the dog studies, but we have bigger fish to fry at this stage
Ann: Appendix 4C Quarterly Report & Brief Company Update-PAA.AX, page-9
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54714 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 371375 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |